The following is a summary of "Bronchiectasis In Patients With Inflammatory Bowel Diseases – Prevalence, Predictors, And ...

According to the CDE website, HSK31858, a Class 1 new drug, was included in the breakthrough therapy designation in 2024 for non-cystic fibrosis bronchiectasis, becoming the first drug in China's ...

DPP1 inhibitor brensocatib has been submitted for approval by the FDA for non-cystic fibrosis bronchiectasis based on the results of the ASPEN trial, which showed that the drug cut the number of ...

The trial involved 1,700 patients without cystic fibrosis, a genetic disorder that is a common cause of bronchiectasis and has a number of approved therapies. Insmed's drug also achieved a ...

Percent-predicted FEV1 measured before pregnancy did not fall 1 year after in women with highly effective cystic fibrosis ...

Find effective medications for 'Bronchiectasis treatment right here!' This page is a trusted source for both professionals and patients, detailing brand-name and generic options designed to manage ...

Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Murray et al, Eur Respir J 2009, DOI: 10.1183/09031936.00163208 Colour of phlegm can predict outcomes for patients with ...

cystic fibrosis, asthma, interstitial lung disease, bronchiectasis, benign and malignant neoplasms, and lung transplantation. The Lung Institute has developed a comprehensive program across ...

Cystic fibrosis (CF ... leading to chronic infections and bronchiectasis with resulting marked decline in pulmonary function. The only treatment for end-stage CF lung disease is lung transplantation.